Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial


Mok T. S. K. , Wu Y., Kudaba I., Kowalski D. M. , Cho B. C. , Turna H. Z. , ...Daha Fazla

LANCET, cilt.393, ss.1819-1830, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 393 Konu: 10183
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/s0140-6736(18)32409-7
  • Dergi Adı: LANCET
  • Sayfa Sayıları: ss.1819-1830

Özet

Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater.